Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MLYCD | O95822 | 8/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | POLQ | O75417 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9770531 | 0.83 | NR1H3 (0.49) | SMN1; SMN2MLYCDNR1H3NR1H2NPSR1 | |
| SCHEMBL2038462 | 0.82 | MAPT (0.40) | SMN1; SMN2MLYCDNR1H3NR1H2LMNA | |
| SCHEMBL16296475 | 0.80 | MLYCD (0.48) | SMN1; SMN2MLYCDNR1H3NR1H2LMNA | |
| SCHEMBL2901265 | 0.79 | SMN1; SMN2 (0.37) | SMN1; SMN2MLYCDNR1H3NR1H2LMNA | |
| SCHEMBL16883807 | 0.75 | SMN1; SMN2 (0.41) | SMN1; SMN2MLYCDNR1H3NR1H2LMNA | |
| SCHEMBL23060401 | 0.73 | RIPK1 (0.35) | SMN1; SMN2TACR1 | |
| SCHEMBL26626027 | 0.73 | ATF1 (0.45) | SMN1; SMN2POLQTACR1 | |
| SCHEMBL23060418 | 0.71 | ATF1 (0.37) | SMN1; SMN2TACR1 | |
| SCHEMBL6861323 | 0.70 | KMT2A (0.36) | SMN1; SMN2LMNAMAPTHTTNPSR1 | |
| SCHEMBL486173 | 0.70 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAMAPTHTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305124-A1 | Acylated Aminopyridine and Aminopyridazine Insecticides | BAYER CROPSCIENCE AG (DE) | 2010-12-02 | — | — | US | disclosed |
| EP-2236505-A1 | Acylated aminopyridines and pyridazines as insecticides | Bayer CropScience AG (DE) | 2010-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305124-A1 | Acylated Aminopyridine and Aminopyridazine Insecticides | AAAS, DDT, QDPR | SMN1; SMN2 2519/4885MLYCD 654/4885NR1H3 4005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.